In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

Zydus Lifesciences launches Zyrifa, a Denosumab biosimilar for osteoporosis and skeletal complications in cancer patients.

Zydus Life noted that population-scale studies show high rates of bone involvement, affecting 50-70% of advanced breast or ...

Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab) ...

“In a hypothetical health plan covering 1 million lives, adding biosimilar denosumab to a health plan formulary may contribute to significant cost savings; savings can be reinvested to further expand ...

If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...

Looking toward dividend payers is a particularly good idea, because companies that consistently increase their payouts tend ...

Privately owned, standalone infusion centers are providing an alternative to hospitals and doctors' offices for patients with ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

In November 2025, the U.S. Food and Drug Administration (FDA) issued several approvals across oncology and supportive care.

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...